Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alamo Ent Associates

Neither a doctor nor a teaching hospital

Research payments

$678,412

98 payments

Through program year 2025, Alamo Ent Associates is reported as receiving $678,412 in research payments, across 98 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $237,843 30
2024 Research $138,631 22
2023 Research $126,436 18
2022 Research $135,361 21
2021 Research $40,140 7

Breakdown

Who paid Research payments · program years 2021–2025
  1. Sanofi US Services Inc. $235,404 35 payments
  2. GlaxoSmithKline, LLC. $166,107 25 payments
  3. Aerin Medical Inc. $94,108 15 payments
  4. Eli Lilly and Company $66,381 2 payments
  5. Intersect ENT, Inc. $55,250 10 payments
  6. Hill Dermaceuticals, Inc. $24,363 1 payment
  7. Genzyme Corporation $12,300 2 payments
  8. Medtronic, Inc. $11,000 5 payments
  9. Insmed, Inc. $9,000 2 payments
  10. OptiNose US, Inc. $4,500 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para $138,164 18 payments
  2. CTP 1125 - Swell $82,708 12 payments
  3. A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) $80,978 15 payments
  4. A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) $71,495 7 payments
  5. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ Ly3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on A Background Therapy With Intranasal Corticosteroids $66,381 2 payments
  6. Expand $66,250 15 payments
  7. A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS) $33,664 4 payments
  8. A Randomised, Double-Blind, Parallel Group Phase III Study to Assess T $27,943 7 payments
  9. A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study $23,202 6 payments
  10. A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps $13,265 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record